Comparative Pharmacology
Head-to-head clinical analysis: DIFLUNISAL versus DYCLOPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUNISAL versus DYCLOPRO.
DIFLUNISAL vs DYCLOPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
50 mg intravenously every 8 hours
None Documented
None Documented
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Category C
Category C
NSAID
NSAID